AI Engines For more Details: Perplexity Kagi Labs You
Organ Transplantation: Cyclosporin A is commonly used as part of immunosuppressive therapy regimens in organ transplant recipients to prevent rejection of the transplanted organ. It works by inhibiting the activation of T lymphocytes (T cells), a type of white blood cell involved in the immune response. By suppressing T-cell activation and proliferation, cyclosporin A helps prevent the immune system from attacking and damaging the transplanted organ.
Autoimmune Diseases: Cyclosporin A is also used in the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis). In these conditions, cyclosporin A suppresses the abnormal immune response that leads to inflammation and tissue damage. It helps reduce symptoms such as joint pain and swelling in rheumatoid arthritis, skin lesions and plaques in psoriasis, and gastrointestinal inflammation in inflammatory bowel disease.
Dermatological Conditions: Cyclosporin A may be used in the treatment of severe dermatological conditions such as atopic dermatitis (eczema), severe allergic contact dermatitis, and chronic urticaria (hives) that are unresponsive to conventional therapies. It helps suppress inflammation and immune-mediated skin reactions, leading to improvement in symptoms such as itching, redness, and skin lesions.
Ophthalmic Conditions: Cyclosporin A eye drops (e.g., Restasis) are approved for the treatment of chronic dry eye disease (keratoconjunctivitis sicca) due to decreased tear production associated with ocular inflammation. Cyclosporin A helps reduce ocular surface inflammation and increase tear production, leading to improved eye comfort and lubrication in patients with chronic dry eye disease.
Dosage and Administration: Cyclosporin A is typically administered orally in the form of capsules or solution, although it may also be given intravenously (IV) in certain clinical situations. The dosage and duration of treatment depend on factors such as the type of medical condition being treated, the severity of symptoms, and the individual patient's response to therapy. It is important to follow the dosage instructions provided by the healthcare provider and to take cyclosporin A as directed to achieve optimal therapeutic outcomes.
Side Effects: Common side effects of cyclosporin A may include hypertension (high blood pressure), nephrotoxicity (kidney damage), hyperlipidemia (high cholesterol levels), gingival hyperplasia (overgrowth of gum tissue), tremor, headache, gastrointestinal disturbances (such as nausea, vomiting, diarrhea), and increased risk of infections. Long-term use of cyclosporin A may also be associated with an increased risk of certain malignancies, particularly skin cancers and lymphomas. Patients should be monitored regularly for side effects during cyclosporin A therapy, and treatment should be adjusted as needed based on individual response and tolerance.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.5 | -0.5 | |
| ADHD | 4.5 | 0.3 | 14 |
| Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.3 | 2 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 2.3 | -0.92 |
| Allergies | 4.7 | 2.1 | 1.24 |
| Allergy to milk products | 1.1 | 0.9 | 0.22 |
| Alopecia (Hair Loss) | 1.9 | 1.9 | |
| Alzheimer's disease | 2.3 | 5.6 | -1.43 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 0.6 | 2.33 |
| Ankylosing spondylitis | 4.3 | 0.2 | 20.5 |
| Anorexia Nervosa | 0.3 | 2.2 | -6.33 |
| Antiphospholipid syndrome (APS) | 1.6 | 1.6 | |
| Asthma | 1 | 1 | 0 |
| Atherosclerosis | 0.9 | 2.7 | -2 |
| Atrial fibrillation | 3.4 | 1.7 | 1 |
| Autism | 6.9 | 8 | -0.16 |
| Barrett esophagus cancer | 0.5 | 0.2 | 1.5 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.7 | 1.3 | -0.86 |
| Brain Trauma | 0.9 | 0.7 | 0.29 |
| Cancer (General) | 0.3 | 3.8 | -11.67 |
| Carcinoma | 3.1 | 2.7 | 0.15 |
| Celiac Disease | 1.8 | 3.8 | -1.11 |
| Cerebral Palsy | 1.8 | 1.2 | 0.5 |
| Chronic Fatigue Syndrome | 3.8 | 6.9 | -0.82 |
| Chronic Kidney Disease | 0.8 | 2.2 | -1.75 |
| Chronic Lyme | 0.7 | -0.7 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 0.8 | 1 |
| Chronic Urticaria (Hives) | 1.8 | 0.8 | 1.25 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 1.2 | -0.09 |
| Colorectal Cancer | 3.1 | 1.4 | 1.21 |
| Constipation | 0.6 | 1 | -0.67 |
| Coronary artery disease | 1 | 1.3 | -0.3 |
| COVID-19 | 9.1 | 11.3 | -0.24 |
| Crohn's Disease | 5.2 | 4.6 | 0.13 |
| cystic fibrosis | 0.6 | 1.2 | -1 |
| deep vein thrombosis | 0.6 | 0.7 | -0.17 |
| Depression | 6.6 | 9 | -0.36 |
| Dermatomyositis | 0.2 | 0.5 | -1.5 |
| Eczema | 0.7 | 2 | -1.86 |
| Endometriosis | 3 | 0.8 | 2.75 |
| Eosinophilic Esophagitis | 0.5 | -0.5 | |
| Epilepsy | 2.3 | 1.7 | 0.35 |
| Fibromyalgia | 2.2 | 2.4 | -0.09 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 2.8 | 0.75 |
| gallstone disease (gsd) | 2.4 | 1 | 1.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1.2 | -0.71 |
| Generalized anxiety disorder | 1.1 | 2.5 | -1.27 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 1.4 | 1.9 | -0.36 |
| Halitosis | 0.7 | 0.2 | 2.5 |
| Hashimoto's thyroiditis | 2.3 | 0.7 | 2.29 |
| Hidradenitis Suppurativa | 0.2 | 0.5 | -1.5 |
| High Histamine/low DAO | 2.4 | 0.5 | 3.8 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.2 | 3 |
| hyperglycemia | 0.2 | 1.7 | -7.5 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 1.9 | 5.5 | -1.89 |
| Hypothyroidism | 1.2 | -1.2 | |
| Hypoxia | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 2.2 | -2.2 | |
| Inflammatory Bowel Disease | 2.7 | 8.3 | -2.07 |
| Insomnia | 1 | 0.7 | 0.43 |
| Intelligence | 0.8 | 0.6 | 0.33 |
| Intracranial aneurysms | 1 | 0.5 | 1 |
| Irritable Bowel Syndrome | 2.9 | 2.9 | 0 |
| Liver Cirrhosis | 4.5 | 3.2 | 0.41 |
| Long COVID | 4.4 | 7.8 | -0.77 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.2 | 1.1 | -4.5 |
| Mast Cell Issues / mastitis | 0.4 | 0.7 | -0.75 |
| ME/CFS with IBS | 0.7 | 3.2 | -3.57 |
| ME/CFS without IBS | 0.7 | 2.5 | -2.57 |
| Menopause | 2.5 | 2.5 | |
| Metabolic Syndrome | 5.9 | 7.4 | -0.25 |
| Mood Disorders | 9.5 | 9 | 0.06 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.5 | 2 |
| Multiple Sclerosis | 4 | 4.9 | -0.23 |
| Multiple system atrophy (MSA) | 1.5 | 1 | 0.5 |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 0.8 | 0.2 | 3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.9 | 5.8 | -1 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.7 | 1.29 |
| Obesity | 7.8 | 4.6 | 0.7 |
| obsessive-compulsive disorder | 4 | 3.6 | 0.11 |
| Osteoarthritis | 1.1 | 1.1 | |
| Osteoporosis | 1.4 | 0.9 | 0.56 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 6 | 5.3 | 0.13 |
| Polycystic ovary syndrome | 1.8 | 1.9 | -0.06 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.7 | -0.4 |
| Premenstrual dysphoric disorder | 1.4 | 0.3 | 3.67 |
| primary biliary cholangitis | 0.4 | 0.5 | -0.25 |
| Psoriasis | 4.6 | 2.5 | 0.84 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 3.8 | 0.37 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 6.5 | 2.2 | 1.95 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 3.6 | 3.2 | 0.13 |
| Sleep Apnea | 1.2 | 1.5 | -0.25 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.5 | 1.2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 1 | -0.67 |
| Stress / posttraumatic stress disorder | 2.9 | 2.1 | 0.38 |
| Systemic Lupus Erythematosus | 2.6 | 1.8 | 0.44 |
| Tic Disorder | 0.5 | 2 | -3 |
| Tourette syndrome | 0.1 | 0.2 | -1 |
| Type 1 Diabetes | 2.6 | 2.2 | 0.18 |
| Type 2 Diabetes | 5.5 | 4.6 | 0.2 |
| Ulcerative colitis | 3.3 | 4.2 | -0.27 |
| Unhealthy Ageing | 2 | 2.6 | -0.3 |
| Vitiligo | 0.8 | 1.9 | -1.37 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]
